Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

Tuesday, November 30, 2021 1 min read

Key Takeaway: Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

Full Press Release Details

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413.